Biomarker Analysis for Kidney Cancer

Not currently recruiting at 256 trial locations

Age: < 65

Sex: Any

Trial Phase: Academic

Sponsor: Children's Oncology Group

Disqualifiers: Renal tumor chemotherapy, Radiation, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to study kidney tumors in younger patients to better understand DNA changes and identify cancer-related biomarkers. Researchers will collect tumor tissue, blood, and urine samples from participants for analysis. Individuals who have recently discovered a kidney tumor through a CT scan or MRI might be suitable candidates for this trial. The research could enhance understanding and treatment of various kidney tumors in the future. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could lead to significant advancements in kidney tumor treatment.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on understanding kidney tumors in younger patients through cutting-edge methods. Unlike treatments that target the tumor directly, this trial uses advanced techniques like DNA analysis and imaging to classify tumors and understand their biology. By collecting tumor tissue, blood, and urine samples, researchers aim to uncover genetic markers, which could lead to more personalized and effective treatment strategies in the future. This approach has the potential to revolutionize how we diagnose and treat kidney tumors by providing insights into their genetic makeup and behavior.

Who Is on the Research Team?

Elizabeth A Mullen

Principal Investigator

Children's Oncology Group

Are You a Good Fit for This Trial?

Inclusion Criteria

Patients with the first occurrence of any tumor of the kidney identified on CT scan or MRI are eligible for this study; histologic diagnosis is not required prior to enrollment but is required for all patients once on study

Nephroblastic tumors

Nephroblastoma (Wilms' tumor) (favorable histology, anaplasia [diffuse, focal])

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection and Analysis

Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses are performed by extraction of DNA.

Baseline

Follow-up

Participants are monitored periodically for 5 years to assess event-free survival and overall survival.

5 years

What Are the Treatments Tested in This Trial?

Interventions

• Cytology Specimen Collection Procedure
• Laboratory Biomarker Analysis

How Is the Trial Designed?

Group I: Ancillary-correlative (renal tumor classification, biology) Experimental Treatment 2 Interventions

Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials

467

Recruited

241,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+